

Jennifer H Anolik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3089606/publications.pdf>

Version: 2024-02-01

93
papers

9,122
citations

53751

45
h-index

49868

87
g-index

109
all docs

109
docs citations

109
times ranked

10498
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. <i>Nature Immunology</i> , 2019, 20, 928-942.	7.0	760
2	B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. <i>Arthritis and Rheumatism</i> , 2004, 50, 2580-2589.	6.7	729
3	Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. <i>Immunity</i> , 2018, 49, 725-739.e6.	6.6	661
4	A New Population of Cells Lacking Expression of CD27 Represents a Notable Component of the B Cell Memory Compartment in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2007, 178, 6624-6633.	0.4	512
5	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019, 20, 902-914.	7.0	501
6	Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 3580-3590.	6.7	426
7	The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003, 48, 455-459.	6.7	420
8	Phenotypic and functional heterogeneity of human memory B cells. <i>Seminars in Immunology</i> , 2008, 20, 67-82.	2.7	321
9	Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2005, 115, 3205-3216.	3.9	297
10	Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. <i>Arthritis and Rheumatism</i> , 2007, 56, 3044-3056.	6.7	268
11	Novel Human Transitional B Cell Populations Revealed by B Cell Depletion Therapy. <i>Journal of Immunology</i> , 2009, 182, 5982-5993.	0.4	248
12	Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. <i>Arthritis and Rheumatism</i> , 2012, 64, 493-503.	6.7	219
13	Lupus IgG VH4.34 Antibodies Bind to a 220-kDa Glycoform of CD45/B220 on the Surface of Human B Lymphocytes. <i>Journal of Immunology</i> , 2004, 172, 4298-4307.	0.4	206
14	PD-1hiCXCR5+ T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. <i>JCI Insight</i> , 2019, 4, .	2.3	171
15	B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. <i>Clinical Immunology</i> , 2007, 122, 139-145.	1.4	167
16	Cutting Edge: Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Inhibits Memory B Lymphocytes via Effects on Lymphoid Germinal Centers and Follicular Dendritic Cell Networks. <i>Journal of Immunology</i> , 2008, 180, 688-692.	0.4	145
17	Production of RANKL by Memory B Cells: A Link Between B Cells and Bone Erosion in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 805-816.	2.9	138
18	B cells in the pathogenesis and treatment of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 307-315.	2.0	114

#	ARTICLE	IF	CITATIONS
19	Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response. PLoS ONE, 2015, 10, e0128269.	1.1	111
20	B cells inhibit bone formation in rheumatoid arthritis by suppressing osteoblast differentiation. Nature Communications, 2018, 9, 5127.	5.8	105
21	B cells as therapeutic targets for rheumatic diseases. Current Opinion in Rheumatology, 2004, 16, 180-185.	2.0	102
22	A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clinical Immunology, 2008, 126, 189-201.	1.4	102
23	Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. Arthritis Research and Therapy, 2018, 20, 139.	1.6	93
24	Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis and Rheumatism, 2010, 62, 2443-2457.	6.7	90
25	B-Cell-Targeted Therapy for Systemic Lupus Erythematosus. Drugs, 2006, 66, 1933-1948.	4.9	88
26	New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Practice and Research in Clinical Rheumatology, 2005, 19, 859-878.	1.4	83
27	Neutrophil-Mediated IFN Activation in the Bone Marrow Alters B Cell Development in Human and Murine Systemic Lupus Erythematosus. Journal of Immunology, 2014, 192, 906-918.	0.4	81
28	Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Research and Therapy, 2011, 13, R209.	1.6	80
29	Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunologic Research, 2009, 45, 144-158.	1.3	78
30	B cell targeted therapies in autoimmune disease. Current Opinion in Immunology, 2019, 61, 92-99.	2.4	75
31	Granzyme K ⁺ CD8 T cells form a core population in inflamed human tissue. Science Translational Medicine, 2022, 14, .	5.8	74
32	NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF- κ B. Journal of Clinical Investigation, 2014, 124, 3200-3214.	3.9	67
33	Human innate B cells: a link between host defense and autoimmunity?. Seminars in Immunopathology, 2005, 26, 433-452.	4.0	66
34	Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome. Multiple Sclerosis Journal, 2008, 14, 425-427.	1.4	64
35	Effects of Multiple Estrogen Responsive Elements, Their Spacing, and Location on Estrogen Response of Reporter Genes. Molecular Endocrinology, 1997, 11, 1994-2003.	3.7	63
36	B cell depletion therapy in systemic lupus erythematosus. Current Rheumatology Reports, 2003, 5, 350-356.	2.1	63

#	ARTICLE	IF	CITATIONS
37	B cell depletion therapy in autoimmune diseases. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 2546.	3.0	61
38	Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus. <i>JCI Insight</i> , 2018, 3, .	2.3	59
39	Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study. <i>Journal of Proteome Research</i> , 2016, 15, 2102-2114.	1.8	56
40	Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence-Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein-Interferon γ Feedback Loop. <i>Arthritis and Rheumatology</i> , 2017, 69, 1623-1635.	2.9	56
41	B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. <i>Lupus</i> , 2004, 13, 381-390.	0.8	54
42	B cell biology: implications for treatment of systemic lupus erythematosus. <i>Lupus</i> , 2013, 22, 342-349.	0.8	53
43	Down-regulation of CD20 on B cells upon CD40 activation. <i>European Journal of Immunology</i> , 2003, 33, 2398-2409.	1.6	51
44	Cooperative binding of estrogen receptor to DNA depends on spacing of binding sites, flanking sequence, and ligand. <i>Biochemistry</i> , 1995, 34, 2511-2520.	1.2	48
45	Primary Sjögren's Syndrome Is Characterized by Distinct Phenotypic and Transcriptional Profiles of IgD+ Unswitched Memory B Cells. <i>Arthritis and Rheumatology</i> , 2014, 66, 2558-2569.	2.9	48
46	B cells in human and murine systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2004, 16, 505-512.	2.0	47
47	New insights into B cell biology in systemic lupus erythematosus and Sjögren's syndrome. <i>Current Opinion in Rheumatology</i> , 2015, 27, 461-467.	2.0	45
48	B cell biology and dysfunction in SLE. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2007, 65, 182-6.	0.7	45
49	Quantitative proteomics of parotid saliva in primary Sjögren's syndrome. <i>Proteomics</i> , 2012, 12, 3113-3120.	1.3	40
50	Treatment of SLE with Anti-CD20 Monoclonal Antibody. , 2004, 8, 193-205.		39
51	Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 829-839.	2.9	38
52	Profound Hypogammaglobulinemia 7 Years after Treatment for Indolent Lymphoma. <i>Cancer Investigation</i> , 2008, 26, 431-433.	0.6	36
53	Stability of the ligand-estrogen receptor interaction depends on estrogen response element flanking sequences and cellular factors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1996, 59, 413-429.	1.2	35
54	A perspective on B-cell-targeting therapy for SLE. <i>Modern Rheumatology</i> , 2010, 20, 1-10.	0.9	32

#	ARTICLE	IF	CITATIONS
55	Differential impact of flanking sequences on estradiol- vs 4-hydroxytamoxifen-liganded estrogen receptor binding to estrogen responsive element DNA. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1993, 46, 713-730.	1.2	31
56	Long-Term B Cell Depletion in Murine Lupus Eliminates Autoantibody-Secreting Cells and Is Associated with Alterations in the Kidney Plasma Cell Niche. <i>Journal of Immunology</i> , 2014, 192, 3011-3020.	0.4	30
57	Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN. <i>Journal of Autoimmunity</i> , 2019, 102, 150-158.	3.0	30
58	Autoreactivity in naïve human fetal B cells is associated with commensal bacteria recognition. <i>Science</i> , 2020, 369, 320-325.	6.0	29
59	A perspective on B-cell-targeting therapy for SLE. <i>Modern Rheumatology</i> , 2010, 20, 1-10.	0.9	23
60	Neutrophils Slow Disease Progression in Murine Lupus via Modulation of Autoreactive Germinal Centers. <i>Journal of Immunology</i> , 2017, 199, 458-466.	0.4	22
61	Reconstitution of the adult B cell repertoire after treatment with rituximab. <i>Arthritis Research and Therapy</i> , 2005, 7, 175.	1.6	20
62	B-cell Biology and Related Therapies in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 109-130.	0.8	20
63	Treatment targets in systemic lupus erythematosus: biology and clinical perspective. <i>Arthritis Research and Therapy</i> , 2012, 14, S3.	1.6	20
64	Dynamic spectrum of ectopic lymphoid B cell activation and hypermutation in the RA synovium characterized by NR4A nuclear receptor expression. <i>Cell Reports</i> , 2022, 39, 110766.	2.9	20
65	Posttransfusion purpura secondary to an alloantibody reactive with HPA-5a (Brb). <i>Transfusion</i> , 2001, 41, 633-636.	0.8	16
66	New Therapies for Systemic Lupus Erythematosus: Cellular Targets. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 201-215.	0.8	16
67	Impaired ATM activation in B cells is associated with bone resorption in rheumatoid arthritis. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	15
68	Vaccine responses in patients with rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2007, 9, 407-415.	2.1	14
69	Cell Senescence in Lupus. <i>Current Rheumatology Reports</i> , 2019, 21, 1.	2.1	13
70	Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells. <i>Arthritis and Rheumatology</i> , 2022, 74, 200-211.	2.9	12
71	B Cell Activation and Plasma Cell Differentiation Are Promoted by IFN- γ in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2021, 207, 2660-2672.	0.4	12
72	Inhibition of G Protein $\beta\gamma$ Subunit Signaling Abrogates Nephritis in Lupus-Prone Mice. <i>Arthritis and Rheumatology</i> , 2016, 68, 2244-2256.	2.9	11

#	ARTICLE	IF	CITATIONS
73	Failure of B Cell Tolerance in CVID. <i>Frontiers in Immunology</i> , 2019, 10, 2881.	2.2	9
74	Bone marrow mesenchymal stem cells from patients with SLE maintain an interferon signature during in vitro culture. <i>Cytokine</i> , 2020, 132, 154725.	1.4	9
75	IFN γ signaling inhibits osteogenesis in human SLE bone marrow. <i>Lupus</i> , 2020, 29, 1040-1049.	0.8	8
76	Prominent B-Cell Signature Differentiates Discoid from Subacute Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2885-2895.e2.	0.3	8
77	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. <i>Rheumatology</i> , 2022, 61, 4335-4343.	0.9	6
78	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. <i>Lupus Science and Medicine</i> , 2021, 8, e000522.	1.1	5
79	From Cold-Agglutinin Disease to Systemic Lupus Erythematosus: Lessons in Human B-Cell Tolerance and Its Breakdown. <i>Transfusion Medicine and Hemotherapy</i> , 2004, 31, 84-90.	0.7	3
80	Targeted Biologic Approaches to the Treatment of Systemic Vasculitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 35, 79-87.	2.9	3
81	Immunologic Reconstitution After Rituximab in Systemic Lupus Erythematosus: Why Should We Care?. <i>Journal of Rheumatology</i> , 2011, 38, 587-589.	1.0	3
82	PKK deficiency in B cells prevents lupus development in Sle lupus mice. <i>Immunology Letters</i> , 2017, 185, 1-11.	1.1	3
83	AI-19 α T peripheral helper cells are expanded in the circulation of active SLE patients and correlate with CD21 ^{low} B cells. , 2018, , .		2
84	Two negative randomized controlled trials in lupus: now what?. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	2
85	B Cell Immunology for the Clinician. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 158-160.	1.1	1
86	Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progress. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 553-555.	0.5	1
87	Small molecule inhibitors of nuclear export ameliorate lupus by modulating plasma cell generation and survival. <i>Arthritis and Rheumatology</i> , 2022, , .	2.9	1
88	Mavs Mediates a Senescence Associated Secretory Phenotype By Inducing Interferon Beta Expression in Human SLE Bone Marrow Stromal Cells. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB269.	1.5	0
89	II-04 α ...Bone marrow mesenchymal stem cells from patients with SLE maintain an interferon signature during in vitro culture. , 2018, , .		0
90	AI-07 α ...A new B cell effector pathway with defective negative regulation of TLR7 signaling in human SLE. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
91	SAT0062â€¦STRATIFIED MEDICINE FOR RHEUMATOID ARTHRITIS: PREDICTING RESPONSE TO BIOLOGIC THERAPY USING IMMUNE CELL SIGNATURES. , 2019, , .		0
92	B-cell biology, tolerance, and autoantibodies. , 2021, , 71-80.		0
93	Characterization of Small Molecule GÎ²Î³ Inhibitors in the Context of Inflammation. FASEB Journal, 2015, 29, 618.4.	0.2	0